On August 21, ACRO and Myriad Genetics hosted a webinar on "Predicting Absolute Benefit in Risk of Metastasis of Androgen Deprivation Therapy added to Radiation Therapy in Patients with Newly Diagnosed Prostate Cancer." Speaker Jonathan Tward, MD, PhD, FASTRO discussed the following:
• In this study, men with scores below the multi-modal threshold did not significantly reduce their 10-year risk of metastasis with the addition of ADT.
• Identifying men in each NCCN® risk group who can avoid ADT when receiving dose-escalated RT.
• Prolaris can accurately predict the absolute risk reduction (ARR) in metastasis risk with the addition of ADT to RT versus RT alone across all NCCN® risk group categories.